Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Плейотропные эффекты эссенциальных фосфолипидов у больных с метаболическим синдромом
Плейотропные эффекты эссенциальных фосфолипидов у больных с метаболическим синдромом
Е.В.Балукова, Ю.П.Успенский. Плейотропные эффекты эссенциальных фосфолипидов у больных с метаболическим синдромом. Consilium Medicum. Гастроэнтерология (Прил.). 2011; 2: 31-35.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Буеверов А.О. Неалкогольный стеатогепатит. Методические рекомендации. М., 2005.
2. Буеверов А.О., Ешану В.С., Маевская М.В., Ивашкин В.Т. Эссенциальные фосфолипиды в комплексной терапии стеатогепатита смешанного генеза. Клин. перспективы гастроэнтерол., гепатол. 2008; 1: 17–22.
3. Лазебник Л.Б., Звенигородская Л.А. Метаболический синдром и органы пищеварения. М., 2009.
4. Мамедов М.Н. Руководство по диагностике и лечению метаболического синдрома. М.: Мультипринт, 2005; с. 13–24, 59–65.
5. Полунина Т.Е., Маев И.В. Неалкогольный стеатоз печени в практике интерниста. Эффективная фармакотерапия в гастроэнтерологии. 2009; 1: 14–9.
6. Успенский Ю.П. Эссенциальные фосфолипиды: старые субстанции – новые технологические решения. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2009; 5: 24–6.
7. Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 2004; 14: 215–24.
8. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008; 48 (2): 662–9.
9. Buchman AL, Dubin M, Jenden D et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992; 102: 1363–70.
10. Bumgardner GL, Li J, Apte S et al. Effect of tumor necrosis factor-a and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice. Hepatology 1998; 28 (2): 466–74.
11. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998; 15: 246–58.
12. Cohen LH, van Leeuwen RE, van Thiel GC et al. Equallypotent inhibitors of cholesterol synthesis in human hepatocytes have distinquishable effects on different cytochrome P-450 enzymes. Biopharm Drug Dispos 2000; 21: 353–64.
13. DaCosta KA, Cochary EF, Blusztajn JK et al. Accumulation of 1,20 sn-diradylglycerol with increased membrane-associated protein kinase C may be the mechanism for spontaneous hepatocarcinogenesis in choline deficient rats. J Biol Chem 1993; 268: 2100–5.
14. de Denus S, Spinier SA, Miller K. Statins and liver toxicity: a meta analysis. Pharmactiherapy 2004; 24 (5): 584–91.
15. Gotto AM Jr. The case for over.the.counter statins. Am J Cardiol 2004; 94: 753–6.
16. Hsia SL, He JL, Mandel M, Froelich CW. Lowering serum cholesterol by topical treatment with soy phosphatidylcholine. Presented at: 7th International Congress on Phospholipids; Monday, Sep. 9, 1996; Brussels, Belgium.
17. Hsia SL, He JL, Nie Y et al. The hypocholesterolemic and antiatherogenic effects of topically applied phosphatidylcholine in rabbits with heritable hypercholesterolemia. Artery 1996; 22: 1–23.
18. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 2002; 4; 288 (21): 2709–16.
19. Mensenkamp AR, Havekes LM, Romijn F et al. Hepatic steatosis and very lowdensity lipoprotein secretion: the involvement of apolipoprotein E. J Hepatology 2001; 35 (6): 816–23.
20. O’Brien BC, Andews VG. Influence of dietary egg and soybean phospholipids and triacylglycerols on human serum lipoproteins. Lipids 1993; 28: 7–12.
21. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003; 7 (2): 415–33.
22. Pasternak RC, Smith SC Jr, Merz BCN. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. JACC 2002; 40: 567–72.
23. Petta S, Muratore C, Craxi A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis 2009; 41 (9): 615–25.
24. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006; 260: 305–19.
25. Simopuolos AP. The importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases. Exp Biol Med (Maywood) 2008; 233 (6): 674–88.
26. Herruzo SJA, Ruiz GI, Carreras PM, Yague MMT. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. Rev Esp Enferm Dig 2006; 98 (11): 844–74.
27. Souza O, Tadeu S, Cavaleiro A. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2010; 25: 357–61.
28. Torres L, Garcia-Trevijano ER, Rodriguez JA et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Biochim Biophys Acta 1999; 1455 (1): 12–22.
29. Zeisei SH, DaCosta KA, Franklin PD. Choline, an essencial nutrient for humans. FASEB J 1991; 5: 2093–8.
2. Буеверов А.О., Ешану В.С., Маевская М.В., Ивашкин В.Т. Эссенциальные фосфолипиды в комплексной терапии стеатогепатита смешанного генеза. Клин. перспективы гастроэнтерол., гепатол. 2008; 1: 17–22.
3. Лазебник Л.Б., Звенигородская Л.А. Метаболический синдром и органы пищеварения. М., 2009.
4. Мамедов М.Н. Руководство по диагностике и лечению метаболического синдрома. М.: Мультипринт, 2005; с. 13–24, 59–65.
5. Полунина Т.Е., Маев И.В. Неалкогольный стеатоз печени в практике интерниста. Эффективная фармакотерапия в гастроэнтерологии. 2009; 1: 14–9.
6. Успенский Ю.П. Эссенциальные фосфолипиды: старые субстанции – новые технологические решения. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2009; 5: 24–6.
7. Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis 2004; 14: 215–24.
8. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008; 48 (2): 662–9.
9. Buchman AL, Dubin M, Jenden D et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992; 102: 1363–70.
10. Bumgardner GL, Li J, Apte S et al. Effect of tumor necrosis factor-a and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice. Hepatology 1998; 28 (2): 466–74.
11. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998; 15: 246–58.
12. Cohen LH, van Leeuwen RE, van Thiel GC et al. Equallypotent inhibitors of cholesterol synthesis in human hepatocytes have distinquishable effects on different cytochrome P-450 enzymes. Biopharm Drug Dispos 2000; 21: 353–64.
13. DaCosta KA, Cochary EF, Blusztajn JK et al. Accumulation of 1,20 sn-diradylglycerol with increased membrane-associated protein kinase C may be the mechanism for spontaneous hepatocarcinogenesis in choline deficient rats. J Biol Chem 1993; 268: 2100–5.
14. de Denus S, Spinier SA, Miller K. Statins and liver toxicity: a meta analysis. Pharmactiherapy 2004; 24 (5): 584–91.
15. Gotto AM Jr. The case for over.the.counter statins. Am J Cardiol 2004; 94: 753–6.
16. Hsia SL, He JL, Mandel M, Froelich CW. Lowering serum cholesterol by topical treatment with soy phosphatidylcholine. Presented at: 7th International Congress on Phospholipids; Monday, Sep. 9, 1996; Brussels, Belgium.
17. Hsia SL, He JL, Nie Y et al. The hypocholesterolemic and antiatherogenic effects of topically applied phosphatidylcholine in rabbits with heritable hypercholesterolemia. Artery 1996; 22: 1–23.
18. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 2002; 4; 288 (21): 2709–16.
19. Mensenkamp AR, Havekes LM, Romijn F et al. Hepatic steatosis and very lowdensity lipoprotein secretion: the involvement of apolipoprotein E. J Hepatology 2001; 35 (6): 816–23.
20. O’Brien BC, Andews VG. Influence of dietary egg and soybean phospholipids and triacylglycerols on human serum lipoproteins. Lipids 1993; 28: 7–12.
21. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003; 7 (2): 415–33.
22. Pasternak RC, Smith SC Jr, Merz BCN. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. JACC 2002; 40: 567–72.
23. Petta S, Muratore C, Craxi A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis 2009; 41 (9): 615–25.
24. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006; 260: 305–19.
25. Simopuolos AP. The importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases. Exp Biol Med (Maywood) 2008; 233 (6): 674–88.
26. Herruzo SJA, Ruiz GI, Carreras PM, Yague MMT. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. Rev Esp Enferm Dig 2006; 98 (11): 844–74.
27. Souza O, Tadeu S, Cavaleiro A. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2010; 25: 357–61.
28. Torres L, Garcia-Trevijano ER, Rodriguez JA et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Biochim Biophys Acta 1999; 1455 (1): 12–22.
29. Zeisei SH, DaCosta KA, Franklin PD. Choline, an essencial nutrient for humans. FASEB J 1991; 5: 2093–8.
Авторы
Е.В.Балукова, Ю.П.Успенский
Санкт-Петербургская государственная медицинская академия им. И.И.Мечникова
Санкт-Петербургская государственная медицинская академия им. И.И.Мечникова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.